证券代码：603922 证券简称：金鸿顺 公告编号：2025-032 苏州金鸿顺汽车部件股份有限公司 2025 年半年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 1、苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）预计 2025 年半年 度实现归属于上市公司股东的净利润为 580.00 万元到 865.00 万元，同比增加 146.69%到 169.64%。 2、公司预计 2025 年半年度实现归属于上市公司股东的扣除非经常性损益的 净利润为 390.00 万元到 584.00 万元，同比增加 118.97%到 128.41%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日。 （二）业绩预告情况 二、上年同期业绩情况 （一）归属于上市公司股东的净利润：-1,242.14 万元；归属于上市公司股东 的扣除非经常性损益的净利润：-2,055.39 万元。 （二）每股收益：-0.10 元。 三、本期业绩预盈的主要原因 2025 年半年 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 截至本公告披露日，苏州金鸿顺汽车部件股份有限公司（以下简称"公司"） 的控股股东海南众德科技有限公司（以下简称"众德科技"）持有公司股份 53,742,080 股，占公司目前总股本的 29.99%。本次部分股份质押后，众德科 技累计质押股份数量为 41,471,000 股，累计质押数量占其持有公司总股数的 77.1667%，占公司总股本的 23.1423%。 一、公司股份质押 （一）本次股份质押基本情况 | 股东名称 | 是否为控 | 本次质押 | 是否为限 | 是否补 | 质押起始日 | 质押到期日 | 质权人 | 占其所持 | 占公司总 | 质押融资 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 股股东 | 股数 | 售股 | 充质押 | | | | 股份比例 | 股本比例 | 资金用途 | | 海南众德科 技有限公司 | 是 | 5,000,000 | ...

Group 1 - The company held an investor briefing regarding the termination of a major asset restructuring plan on July 2025, which was conducted online [1][2] - The chairman, independent director, CFO, and board secretary addressed investor concerns and provided responses within the limits of information disclosure [1] - The company confirmed that the second quarter operating performance and mid-year report details would be available in August 2025 [1] Group 2 - The reason for terminating the major asset restructuring was due to the inability of the parties involved to reach a consensus on the final transaction plan after multiple negotiations [1] - The company emphasized that it conducted thorough research and friendly negotiations with relevant parties before deciding to terminate the restructuring [1] - The company reassured investors that its current production and operational status is normal and there are no indications of delisting risks [1]

证券代码：603922 证券简称：金鸿顺 公告编号：2025-030 苏州金鸿顺汽车部件股份有限公司 关于终止筹划重大资产重组事项的投资者说明会召 开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、投资者说明会召开情况 苏州金鸿顺汽车部件股份有限公司（以下简称"公司"）已于 2025 年 07 月 09 日 上 午 10:00-11:00 通 过 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/），以网络互动方式召开了公司关于终止筹划重大资产 重组事项的投资者说明会。公司董事长刘栩先生、独立董事叶少波先生、财务总 监周海飞先生、董事会秘书邹一飞先生就本次终止筹划重大资产事项的相关情况 沟通和交流，在信息披露允许的范围内就投资者普遍关注的问题进行了回答。 问题 1：您好刘董事长！关于 2025 年 2 季度经营业绩情况是否同比好转？ 答：您好！关于公司二季度经营情况及中报业绩情况，请您在 2025 年 8 月 30 日关注公司在指定 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

Core Viewpoint - Jin Hongshun (603922.SH) announced the termination of its major asset restructuring plan due to the inability to reach a consensus among the parties involved after extensive negotiations and due diligence [3]. Group 1: Announcement and Restructuring Plan - On October 23, 2024, Jin Hongshun disclosed its plan to acquire 95.79% of New Thinking Motor Co., Ltd. through a combination of issuing shares and cash payments, along with raising supporting funds [1]. - The company’s stock was suspended from trading on October 23, 2024, and resumed trading on November 6, 2024, after the board approved the restructuring plan [2]. - The restructuring was deemed significant under the regulations but did not constitute a related party transaction, nor did it change the actual control of Jin Hongshun [1][2]. Group 2: Financial Performance of Target Company - The target company, New Thinking, reported revenues of 465.12 million yuan, 878.92 million yuan, and 975.15 million yuan for the years 2022, 2023, and January-August 2024, respectively [4]. - The net profits for the same periods were -228.64 million yuan, 7.27 million yuan, and 93.18 million yuan, indicating a turnaround in profitability [4]. Group 3: Market Reaction - Following the resumption of trading on November 6, 2024, Jin Hongshun's stock hit the daily limit up for two consecutive trading days [5].

Core Viewpoint - Suzhou Jinhongshun Automotive Parts Co., Ltd. has announced the termination of its major asset restructuring plan to acquire 95.79% of New Thinking Motor Co., Ltd. This marks the fourth failed restructuring attempt in five years for the company, which aimed to transition towards electrification and intelligence in the automotive sector [1][5]. Group 1: Termination of Restructuring - The company has decided to terminate the acquisition of New Thinking after thorough discussions and negotiations with relevant parties, as no consensus on the final transaction plan was reached [2][3]. - The termination of this transaction will not adversely affect the company's existing operations, financial status, or strategic development [3]. Group 2: Company Background and Financials - Jinhongshun primarily engages in the development, production, and sales of automotive body and chassis stamping parts and related molds [3]. - The company reported a revenue of 1.27 billion yuan in Q1 2025, with a net profit of 3.57 million yuan, recovering from a loss of 16.4 million yuan in the same period last year [6]. Group 3: New Thinking Motor Co., Ltd. - New Thinking, founded in 2014, is a leading company in the micro-drive motor sector, with products used in smartphones, security monitoring, and automotive electronics [4]. - The company reported revenues of 465 million yuan in 2022, 879 million yuan in 2023, and 975 million yuan from January to August 2024, with a projected total output value of 1.6 billion yuan in 2024 [4].

Core Viewpoint - Jin Hongshun's restructuring plan to acquire a 95.79% stake in New Thinking Motor Co., Ltd. has been terminated due to a lack of consensus among the parties involved, marking the fourth failed attempt at mergers and acquisitions in five years [1][5]. Group 1: Company Overview - Jin Hongshun (603922.SH) was listed in 2017 and primarily engages in the development, production, and sales of automotive body and chassis stamping parts and related molds [2]. - The company has faced continuous losses in net profit excluding non-recurring items for six consecutive years since 2019, largely due to challenges in the traditional automotive industry [2]. Group 2: Industry Context - The traditional automotive sector is experiencing a downturn due to the impacts of electrification, connectivity, and intelligence, leading to decreased market demand and intensified competition [2]. - The rapid development of new energy vehicles is driving a transformation in the automotive industry, resulting in a "white-hot" competitive environment and reduced profit margins for upstream component manufacturers [2]. Group 3: Acquisition Details - New Thinking Motor, founded in 2014, specializes in the design, development, production, and sales of micro automatic focusing voice coil motors and other types of motors, and is recognized as a leading supplier in China [1][3]. - The company reported revenues of 465 million yuan, 879 million yuan, and 975 million yuan for the years 2022, 2023, and the first eight months of 2024, respectively, with a projected total output value of 1.6 billion yuan in 2024 and 2 billion yuan in 2025 [2][3]. Group 4: Impact of Termination - The termination of the acquisition is stated to have no significant adverse effects on Jin Hongshun's existing operations, financial status, or strategic development [5]. - This marks the fourth failed merger or acquisition attempt for Jin Hongshun in five years, with previous attempts including the acquisition of Huibo Yuntong Technology Co., Ltd. and other ventures that also did not materialize [5][6].

Company Announcements - Jihua Group's existing product system does not involve brain-computer interface related fields [1] - Prit's plan to invest 1 billion yuan to build a plastic modification materials headquarters and R&D manufacturing base in South China [1][2] - Lian De Equipment won a contract worth 157 million yuan for BOE's 8.6 generation AMOLED production line project [1][2] - Jiadu Technology plans to issue shares (H-shares) overseas and list on the Hong Kong Stock Exchange [1][2] - Longdi Group intends to acquire no more than 20.1667% equity in Jujia Technology [1][4] - New Zhonggang plans to repurchase shares worth 40 million to 80 million yuan [1][4] - Xiaogoods City expects a net profit increase of 12.57% to 17.40% in the first half of the year [1][4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials through block trading [1][4] - Lihua Co., Ltd. intends to reduce its holdings by no more than 3.00% [1][4] - Zhimin Da plans to raise no more than 213 million yuan through a private placement [1][5] - Xiangtong Co. plans to issue corporate bonds not exceeding 4 billion yuan [1][5] Performance Forecasts - Hanyu Pharmaceutical expects a half-year profit of 142 million to 162 million yuan, turning a profit compared to the previous year [4] - Taotao Automotive anticipates a net profit increase of 70.34% to 97.81% in the first half of the year [4] - Weichai Heavy Machinery expects a net profit increase of 40% to 60% in the first half of the year [4] Shareholding Changes - Lihua Co., Ltd.'s actual controller Cheng Lili and his concerted actors plan to reduce their holdings by no more than 3.00% [4] - He Shi Eye Hospital's Advanced Manufacturing Fund plans to reduce its holdings by no more than 2% [4] - Haitan Ruisheng's shareholder He Lin and his concerted actors plan to reduce their holdings by no more than 2.9463% [4] - Sinopec Capital plans to reduce its holdings by no more than 3.5256 million shares in Haizheng Materials [4] Other Announcements - Zhimin Da plans to raise no more than 213 million yuan through a private placement [5] - Yuyuan Co. plans to issue corporate bonds not exceeding 40 billion yuan [5] - Jinhongshun has terminated the planning of a major asset restructuring [5]

Mergers and Acquisitions - Yanpai Co., Ltd. plans to acquire 100% equity of TTL and TTL Management Company for approximately €2.9 million, focusing on industrial textile solutions for B2B clients [1] - Landi Group intends to purchase up to 20.17% equity of Ningbo Jujia New Materials Technology Co., Ltd. for a total price not exceeding ¥121 million, as the company specializes in high-performance LCP fiber production [3] Asset Restructuring - Jinhongshun announced the termination of its major asset restructuring plan to acquire 95.79% of New Thinking Motor Co., Ltd. through share issuance and cash payment [2] Shareholding Changes - Haitai Ruisheng's controlling shareholder, He Lin, and his concerted party Zhongyi An plan to reduce their holdings by up to 2.95%, totaling no more than 177.74 million shares [4] - Silan Microelectronics' shareholder, Luo Huabing, plans to reduce his holdings by no more than 500,000 shares, representing up to 0.03% of the company's total equity [5] - Haizheng Shengcai's major shareholder, Sinopec Capital, intends to reduce its holdings by up to 1.74%, totaling no more than 3.5256 million shares [6] Operational Updates - Haiyang Wang confirmed that its operational status is normal and there are no undisclosed significant matters, despite a stock price fluctuation exceeding 20% [7] - Neimeng Yijian reported that its main business has not undergone significant changes, and the external market environment remains stable [10]